Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site induration, Vaccination site pain, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Mild arm pain), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     NO medical history information was reported.     On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (Mild arm pain). On 15-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site). At the time of the report, VACCINATION SITE PAIN (Mild arm pain), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  Patient received treatment including Claritin, Zyrtec, Advil for pain and iced as needed. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Jan-2021 and was forwarded to Moderna on 24-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Mild arm pain), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     NO medical history information was reported.     On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (Mild arm pain). On 15-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site). At the time of the report, VACCINATION SITE PAIN (Mild arm pain), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE INDURATION (Harden Injection site), VACCINATION SITE WARMTH (Hot injection site) and VACCINATION SITE PRURITUS (Extremely itchy injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  Patient received treatment including Claritin, Zyrtec, Advil for pain and iced as needed.